Clinical trials: Estradiol
Vulvovaginal Atrophy, Vasomotor Symptoms
A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women
An open-label study to assess the PK of estradiol, estrone and progesterone from the DARE-HRT1 intravaginal rings at two different dose strengths.
- Trial name
- NCT05418426
- Testing
- IVR Dose 1, IVR Dose 2, Oral Reference
- Where
- 2 sites in Australia
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Daré Bioscience, Inc.
Dysmenorrhea
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in the Treatment of Women With Primary Dysmenorrhea (MK-8342B-060)
The purpose of this study was to evaluate the efficacy of the etonogestrel (ENG) + 17β-estradiol (E2) (MK-8342B) vaginal ring compared to placebo vaginal ring in the treatment of dysmenorrhea at Treatment Cycle 2.
- Trial name
- NCT02668822
- Testing
- ENG 125 μg + E2 300 μg vaginal ring (MK-8342B), Ibuprofen
- Volunteers
- 18 people
- Sponsor
- Organon and Co
Vulvovaginal Atrophy, Vasomotor Symptoms
Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women
Randomized, Open-label 2-arm, parallel group study in approximately 20 healthy postmenopausal women to assess the safety of DARE-HRT1 Intravaginal Rings in two different dose strengths and the PK of progesterone and estradiol…
- Trial name
- DARE-HRT1 (NCT05367973)
- Testing
- IVR Dose 1, IVR Dose 2
- Where
- 2 sites in Australia
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Daré Bioscience, Inc.
Acne Vulgaris
Comparison of Efficacy and Safety of Norgestimate-ethinyl Estradiol and Cyproterone Acetate-ethinyl Estradiol in the Treatment of Acne Vulgaris
The purpose of this study was to evaluate the effectiveness and safety of norgestimate-ethinyl estradiol as comparted with cyproterone acetate-ethinyl estradiol among female patients with moderate acne vulgaris.
- Trial name
- NCT00752635
- Testing
- Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol
- Volunteers
- 48 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Moderate to Severe Primary Dysmenorrhea
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in Women With Primary Dysmenorrhea (With Optional Extension) (MK-8342B-059)
The purpose of this study is to assess the etonogestrel (ENG) + 17β-estradiol (E2) vaginal ring's efficacy compared to a placebo vaginal ring in the treatment of dysmenorrhea at Treatment Cycle 2.
- Trial name
- NCT02668783
- Testing
- Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring, Ibuprofen
- Volunteers
- 25 people
- Sponsor
- Organon and Co
Contraception, Female Contraception
Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.
This study uses the PharMetrics and MarketScan US health care insurance claims database to estimate relative risks for non-fatal venous thromboembolism (including cerebral venous sinus thrombosis), ischemic stroke, and acute…
- Conditions
- Contraception, Female Contraception, Fertility Control
- Trial name
- NCT00511784
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Osteoporosis
The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa
The purpose of this study is to evaluate the effect of norgestimate/ethinyl estradiol on lumbar spine (L1-L4) and total hip bone mineral density (BMD) in pediatric subjects with anorexia nervosa.
- Trial name
- NCT00320567
- Testing
- norgestimate/ethinyl estradiol
- Volunteers
- 123 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Dysmenorrhea
A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain
This study is being conducted to evaluate the effects of treatment with Seasonique an extended-regimen oral contraceptive that utilizes low dose ethinyl estradiol during the typical hormone-free interval.
- Trial name
- NCT00196313
- Testing
- levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets
- Where
- 13 sites in United States
- Volunteers
- 95 people
- Sponsor
- Duramed Research
Vulvar Atrophy, Vaginal Atrophy
Efficacy and Safety Of Spil's Estradiol Vaginal Tablet
Estradiol vaginal tablet is a tablet which hydrates upon contact with moisture, releasing 17ß-estradiol. The estradiol in estradiol vaginal tablet is chemically and biologically identical to the endogenous human estradiol and is…
- Trial name
- NCT01753102
- Testing
- Estradiol
- Where
- India
- Volunteers
- 49 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Menopause, Postmenopausal Vaginal Atrophy
Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency
This study is conducted in Europe. The aim of this study is to investigate the self-reported impact of Vagifem® (estradiol) treatment on urogenital discomfort in women with atrophic vaginitis due to oestrogen deficiency.
- Trial name
- NCT01507454
- Testing
- estradiol, 25 mcg
- Where
- Germany
- Volunteers
- 1,613 people
- Sponsor
- Novo Nordisk A/S
Venous Thrombosis, Pulmonary Embolism
Study Of Lybrel In Relation To Venous Thromboembolism
Lybrel® is an oral contraceptive that delivers low doses of levonorgestrel and ethinyl estradiol (90 μg/20 μg). Lybrel is taken on a continuous basis without a placebo or pill-free interval to inhibit menstrual cycle bleeding by…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Sinus Thrombosis, Intracranial
- Trial name
- NCT01297348
- Testing
- 90ug levonorgestrel / 20 ug ethinyl estradiol, Oral Contraceptives containing 20 ug of ethinyl estradiol
- Volunteers
- 598,682 people
- Sponsor
- Pfizer
Acne Vulgaris
Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne
The objectives of this study were to evaluate the efficacy and safety of drospirenone 3 mg/ethinyl estradiol 0.02 mg (DRSP/EE) in comparison with placebo in female subjects with moderate acne vulgaris during 6 treatment cycles
- Trial name
- NCT00656981
- Testing
- YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
- Where
- 22 sites in United States
- Volunteers
- 541 people, healthy volunteers welcome
- Sponsor
- Bayer
Acne Vulgaris
Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.
The objectives of this study were to evaluate the efficacy and safety of drospirenone 3 mg/ethinyl estradiol 0.02 mg (DRSP/EE) in comparison with placebo in female subjects with moderate acne vulgaris during 6 treatment cycles.
- Trial name
- NCT00651469
- Testing
- YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
- Where
- 27 sites in United States
- Volunteers
- 534 people, healthy volunteers welcome
- Sponsor
- Bayer
Menopause, Urinary Infections
Preventive Effect of Treatment With Estradiol Vaginal Tablets on Recurrent Urinary Tract Infections in Post-menopausal Women
This trial is conducted in Europe. The aim of this trial is to investigate the preventive effect of treatment with estradiol vaginal tablets on recurrent urinary tract infections (RUTI) in post-menopausal women with signs of…
- Trial name
- NCT00560924
- Testing
- estradiol, 25 mcg
- Where
- Sweden
- Volunteers
- 6 people
- Sponsor
- Novo Nordisk A/S
Ovulation
Study Evaluating Effects of Levonorgestrel and Ethinyl Estradiol on Ovulation
To determine the ability of a monophasic oral contraceptives ("OC") regimen of Levonorgestrel ("LNG") 90 mg and Ethinyl Estradiol ("EE") 20 mg to inhibit ovulation during 84 days of continuous therapy.
- Trial name
- NCT00254189
- Testing
- Levonorgestrel, Ethinyl Estradiol
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Contraception
Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive
The purpose of this study is evaluating Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive in Premenopausal Females Aged 14 to 35 Years (Inclusive).
- Trial name
- NCT05264506
- Testing
- NOMAC-E2 COC
- Where
- 103 sites in United States
- Volunteers
- 3,055 people
- Sponsor
- Organon and Co
Postmenopause
Effects of Wellnara on Climacteric Symptoms
Aim of this NIS is to obtain further information on efficacy, tolerability, and acceptance of Wellnara in a large user population under the conditions of routine medical practice.
- Trial name
- NCT00913926
- Testing
- E2/LNG oral (Wellnara, BAY86-5029)
- Where
- Germany
- Volunteers
- 749 people
- Sponsor
- Bayer
Genetic Disorder, Turner Syndrome
Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome
This trial is conducted in Europe. The aim of this trial is to assess whether increasing doses of somatropin (Norditropin®) can maintain the initial increase in height velocity and improve final height.
- Trial name
- NCT01518062
- Testing
- somatropin, oestrogen
- Where
- Netherlands
- Volunteers
- 65 people
- Sponsor
- Novo Nordisk A/S
Dura Mater Nick Cut or Tear, Surgery
Duragen® Secure Post Marketing Clinical Follow-up (PMCF)
The purpose of this study is to gather information about post-market performance of DuraGen Secure.The aim of this post market clinical follow-up (PMCF) is to obtain post market clinical data to evaluate the presence of…
- Trial name
- NCT02225080
- Where
- 5 sites in France, Germany and 2 more
- Volunteers
- 100 people
- Sponsor
- Integra LifeSciences Corporation
Genetic Disorder, Turner Syndrome
Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome
This trial is conducted in Europe. The aim of the trial is to induce normal pubertal development in girls with Turner Syndrome in accordance with that of their peers and their individual state psychosocial maturation.
- Trial name
- NCT01710696
- Testing
- 17-beta estradiol
- Where
- 28 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Novo Nordisk A/S